
Anthony Hagen
Advertisement
Articles by Anthony Hagen


The FDA will reassess 6 indications for immune checkpoint inhibitors that were granted accelerated approval but failed to prove clinical benefit in confirmatory trials.

Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention
2
INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD
3
First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD
4
AI Reshaping Diabetes Care From Nutrition to Clinical Decisions
5
